MDM. Kalpana Devi

M. Kalpana Devi

*This is an algorithmically generated author record based on publicly available information.

M. Kalpana Devi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Model-Informed Precision Dosing of Thiopurines in Inflammatory Bowel Disease through Pharmacometric Integration of TPMT and NUDT15 Genotypes

    by Thilagesh P, Aiswarya Nair U, Anand Kumar S, Akshaya Krishnan, Gokilavani S, Kalpana Devi M, Shankar Ganesh M

    Introduction/Objective: Thiopurines (azathioprine, 6-mercaptopurine) are pivotal for IBD remission induction but possess a narrow therapeutic index and large PK/PD variability. We assess integrating TPMT and NUDT15 genotyping with pharmacometric models to support genotype-directed, model-informed precision dosing beyond empiric approaches and traditional therapeutic drug monitoring. Methods: We performed a narrative review of pharmacometric and pharmacogenetic research, evaluating (i) genotype–phenotype correlation for TPMT and NUDT15 by ancestry; (ii) population PK/PD and Bayesian or nonlinear mixed-effects modeling with genetic, biochemical, and co-medication covariates; and (iii) biomarker approaches comparing red-cell 6-thioguanine nucleotide assays vs. DNA-thioguanine, and clinical outcomes. Results: NUDT15 R139C alleles impart high early-onset leukopenic risk at nominal doses, particularly in East/South Asians, challenging genotype-blind dosing and conventional 6-TGN–based monitoring. TPMT polymorphisms, despite their traditional prominence, exhibit genotype–phenotype discordance and diminished predictive value outside of primarily Caucasian populations. Bayesian and mixed-effects models of the present day provide individualized dosing in real time; however, widely generalizable, genotype-normalized PK/PD paradigms and routine inclusion of higher-resolution biomarkers like DNA-TG are limited. Discussion: Dependence on historic TDM and TPMT-favoring strategies is inadequate in heterogeneous populations and for NUDT15 variant-associated early toxicity. Incorporation of diplotype-directed MIPD with solid PK/PD modeling and improved biomarkers may change thiopurine treatment from dose-measure-reactive to dose-predictive. Challenges involve ancestry-sensitive algorithms, standardized DNA-TG assays, and EHR-based, validated decision support. Conclusion MIPD combining TPMT/NUDT15 diplotypes, adaptive PK/PD modeling, and high-resolution biomarkers can make thiopurine treatment in IBD a modernized reality. Widespread implementation necessitates ancestry-adapted, clinically established algorithms, decision support, and multicenter testing to provide safe, effective, and equitable dosing.

  • Clinical Translation Potential of Surface-Modified Proniosomes in Systemic Cancer Therapeutics

    by M. Kalpana Devi, Balakrishnan Sangameswaran, Madhusudhan Sampathkumar, C.K. Dhanapal, K. Janakiraman

    Proniosomes are anhydrous, non-ionic surfactant precursors that rehydrate into bilayered niosomes, addressing long-standing challenges in systemic cancer drug delivery. We systematically reviewed oncology-targeted proniosome publications, comparing drug loading, stability, release, and pharmacokinetics with liposomes, polymeric nanoparticles, micelles, and solid-lipid nanoparticles. We assessed design determinants (surfactant composition, cholesterol ratio, charge inducers), surface modifications (PEGylation, ligand conjugation, pH- or thermoresponsive groups), and conducted a SWOT analysis. Proniosomes demonstrated high physicochemical stability, robust encapsulation, and controlled release, supporting hydrophilic, hydrophobic, and macromolecular payloads. Self-assembly and vesicle characteristics were controlled by surfactant/cholesterol/charge composition. Surface modification prolonged circulation halflife, augmented tumour accumulation and intracellular delivery, and minimized off-targeting and immunogenicity. Functional developments allowed systemic delivery of chemotherapeutics and biologics, co-delivery with nucleic acids (siRNA, CRISPR-Cas9), and theranostic integration with imaging agents. Compared with peer platforms, proniosomes equalled or surpassed drug loading, stability, and systemic bioavailability, and the dry format minimized manufacturing and scale-up. Modularity of the platform facilitates targeted, multi-functional regimens and individualized dosing, providing a pragmatic path to precision oncology. Issues remaining are regulatory routes, batch reproducibility, and industrial scale-up.